Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees.  Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). The company also owns a lead therapeutic molecule FXR314.

Eli Lilly & Co. terlibat dalam penemuan, pengembangan, pembuatan, dan penjualan produk farmasi. Perusahaan ini berkantor pusat di Indianapolis, Indiana dan saat ini mempekerjakan 47.000 karyawan penuh waktu. Produk kesehatan kardiometaboliknya termasuk Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, dan lainnya; Humulin, Humulin 70/30, dan lainnya; Jardiance; Mounjaro; Trulicity; dan Zepbound. Produk onkologi yang dimilikinya termasuk Cyramza, Erbitux, Tyvyt, dan Verzenio. Produk imunologinya mencakup Ebglyss, Olumiant, Omvoh, dan Taltz. Produk neuroscience-nya termasuk Emgality dan Kisunla. Perusahaan, melalui anak perusahaannya, POINT Biopharma Global Inc., terlibat dalam penemuan, pengembangan, dan upaya manufaktur radiopharmaceutical, serta terapi radioligand klinis dan pra-klinis yang sedang dikembangkan untuk pengobatan kanker. Perusahaan juga mengembangkan penghambat molekul kecil oral dari integrin α4β7 untuk penyakit radang usus (IBD). Perusahaan juga memiliki molekul terapeutik utama FXR314.

Saham Eli Lilly

Tentang Eli Lilly

Statistik Kunci